Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6172252 | 0.91 | OPRD1 (0.50) | ALDH1A1POLBKCNH2OPRD1OPRK1 | |
| SCHEMBL6171276 | 0.84 | OPRD1 (0.45) | ALDH1A1POLBKCNH2OPRD1OPRK1 | |
| SCHEMBL6173840 | 0.84 | DRD2 (0.46) | ALDH1A1POLBKCNH2OPRD1OPRK1 | |
| SCHEMBL6171176 | 0.80 | OPRD1 (0.52) | POLBOPRD1OPRK1OPRM1HTR7 | |
| SCHEMBL6183759 | 0.77 | OPRD1 (0.58) | ALDH1A1POLBOPRD1OPRK1OPRM1 | |
| SCHEMBL6171353 | 0.75 | OPRM1 (0.48) | ALDH1A1POLBOPRD1OPRK1OPRM1 | |
| SCHEMBL6169561 | 0.75 | OPRL1 (0.54) | POLBOPRD1OPRK1OPRM1USP2 | |
| SCHEMBL6171181 | 0.75 | OPRD1 (0.82) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6170827 | 0.74 | OPRD1 (0.46) | ALDH1A1POLBOPRD1OPRK1OPRM1 | |
| SCHEMBL6171201 | 0.73 | POLB (0.46) | ALDH1A1POLBKCNH2MAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1112255-B1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | PFIZER PROD INC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040138220-A1 | 4,4-Biarylpiperidine derivatives | PFIZER, INC. | 2004-07-15 | — | — | US | disclosed |
| US-6720336-B2 | USED AS LIGANDS FOR OPIOID RECEPTORS, FOR THERAPY OF NEUROLOGICAL AND GASTROINTESTINAL DISORDERS | PFIZER, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20020013321-A1 | 4,4-Biarylpiperidine derivatives | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1112255-A1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000014066-A1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | PFIZER PRODUCTS INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138220-A1 | 4,4-Biarylpiperidine derivatives | CYP4B1, CYP3A5, CYP3A4 | ALDH1A1 178/4885POLB 4254/4885KCNH2 600/4885 |
| US-20020013321-A1 | 4,4-Biarylpiperidine derivatives | CYP4B1, CYP3A5, CYP3A4 | ALDH1A1 178/4885POLB 4254/4885KCNH2 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.